Fortrea Holdings Inc.
HealthcareNASDAQ:FTRE · NASDAQ Global Select
-$0.39 today
Vol 0.96M · Avg 1.33M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-175.0%
avg -32.0%
ROIC
-1.7%
avg -0.1%
ROA
-36.3%
avg -6.6%
Analysis
ROIC is currently the strongest return metric at -1.7% versus its period average of -0.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Anshul Thakral | Chief Executive Officer & Director | $1.69M | — | 48 | $1.25M | 1.32% |
Jill McConnell | Chief Financial Officer | $817,879.00 | — | 51 | $72,276.00 | 0.08% |
Mark A. Morais | Chief Operating Officer & President of Clinical Services | $812,667.00 | — | 49 | $71,365.00 | 0.08% |
Hima Inguva | Head of Corporate Development | — | — | — | — | — |
Leonard Scott Dove | President of Clinical Pharmacology Services | — | — | 52 | — | — |
Oren J. Cohen | Chief Medical Officer | — | — | 65 | — | — |
Alejandro Martinez Galindo | Chief Information Officer | — | — | — | — | — |
Dave Cooper | Chief Administrative Officer | — | — | — | — | — |
Drayton Virkler | President & Chief Commercial Officer | — | — | — | — | — |
Robert Parks | Chief Accounting Officer | — | — | — | $20,389.00 | 0.02% |
Agnieszka Gallagher | General Counsel & Corporate Secretary | — | — | 52 | — | — |
Sandy Kennedy | Chief Quality, Regulatory Affairs & Sustainability Officer | — | — | — | — | — |
Tracy H. Krumme | Senior Vice President of Investor Relations | — | — | 58 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$507,168.10
Sells
21
$511,510.43
Net Sentiment
$4,342.33
Net selling
Most Active
Morais Mark A.
8 transactions
1–10 of 24
Analysis
Insiders reported 3 buys worth $507,168.10 and 21 sells worth $511,510.43 over the last 12 months. That adds up to net selling of $4,342.33. Morais Mark A. was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -4.1% | +2.5% (6yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at -4.1% over three years. Forward estimates point to Revenue at +2.5% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
AnaptysBio, Inc.
NASDAQ:ANAB
$2.42B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
ProKidney Corp.
NASDAQ:PROK
$242.99M
Who manages FTRE?
Fortrea Holdings Inc. (FTRE) lists 13 active executives. The top listed executive is Hima Inguva, Head of Corporate Development.
Are FTRE insiders buying or selling?
Recent insider activity shows net buying of $19.21M.
Explore More
Continue the stock analysis
Jump to another research area for this company.